The Pharma Data

AUGUST 13, 2020

There are no licensed vaccines for any human coronavirus.” Inactivated whole virus vaccines: 60 million doses Valneva. Kate Bingham, chair of the UK government Vaccine Taskforce, told the BBC: “We don’t know if any of these vaccine formats that we’ve acquired will actually work.

Vaccine 52

Vaccine Virus Government Clinical Trials 52

The Pharma Data

DECEMBER 20, 2020

BT-001 is a best-in-class oncolytic Vaccinia virus. platform and its patented large-capacity VV cop TK-RR- oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR ® /F.I.R.S.T LUND, Sweden and STRASBOURG, France , Dec.

Virus 52

Virus Trials Clinical Trials Clinical Development 52

Agency IQ

MARCH 7, 2024

BY AMANDA CONTI | MAR 6, 2024 8:46 PM CST AgencyIQ’s quick primer on the influenza virus and how annual vaccine strains are selected Influenza viruses have caused untold illness and death through human history. A key part of the influenza virus’ ability to infect humans is hemagglutinin (HA), a glycoprotein found on the surface of the virus.

Vaccine 40

Vaccine FDA Virus Licensing 40

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 115

Therapies DNA Virus Clinical Trials 115

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic. BA HCP ISI 09JUL2020.

Licensing 40

Licensing Licensing Therapies Laboratories 40

The Pharma Data

MAY 27, 2022

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. About AstraZeneca.

Vaccine 52

Vaccine Virus Immune Response Licensing 52

The Pharma Data

AUGUST 15, 2021

adults and children against the TBE virus when visiting or living in TBE endemic areas. is developed using a master ‘seed’ virus that is similar to the TBE virus found in nature. 1 TICOVAC is the only FDA-approved vaccine to help protect U.S. Following today’s FDA approval, the U.S. in 1-15 year olds and 98.7-100%

FDA Approval 52

FDA Approval Vaccine FDA Virus 52

Drug Target Review

APRIL 5, 2024

For example, a CDMO with deep sequencing knowledge and a proprietary cell line will achieve significantly better performance than CDMOs that license third-party technologies. The first concern is microbial contamination. CDMOs must routinely test throughout CLD to ensure cell cultures are free of microbes.

Protein Production 96

Protein Production Protein Expression Bioinformatics Production 96

The Pharma Data

OCTOBER 28, 2020

In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

SEPTEMBER 30, 2021

That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. As prior work with other respiratory pathogens like influenza has shown, sterilizing immunity to virus re-infection requires adaptive immune responses within the tract and therefore the lung. Breathe in, exhale.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

MARCH 14, 2021

This is much lower than would be expected to occur naturally in a general population of this size and is similar across other licensed COVID-19 vaccines. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

Vaccine 52

Vaccine Virus Licensing Licensing 52

Broad Institute

MAY 14, 2024

Then, during graduate school at the California Institute of Technology in the early 1960s, he was introduced to bacteriophage T7, a virus that infects Escherichia coli bacteria. Driven by basic biology Studier grew up in Iowa and became fascinated with biophysics while an undergraduate at Yale University. and around the world.

RNA 84

RNA Production Molecular Biology Laboratories 84

Codon

FEBRUARY 27, 2024

Patient YY’s neighbors quickly started to become infected, passing on the virus in turn. While the consensus that emerged among experts was that the virus spread primarily via airborne transmission , it also made use of another route: fomite transmission. Puzzled, epidemiologists sought to understand the source of the outbreak.

Virus 68

Virus Hospitals Production Regulations 68

The Pharma Data

SEPTEMBER 6, 2021

Takeda today announced that the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) will purchase 150 million doses of Novavax’ vaccine candidate (TAK-019 in Japan) manufactured in Japan by Takeda subject to licensing and approval. The details of the terms and conditions of the agreement are confidential.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

NOVEMBER 11, 2020

“As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”. About Selva Therapeutics.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.

Trials 52

Trials Virus Long-Term Care Facilities Government 52

The Pharma Data

OCTOBER 6, 2021

Data from the early-stage study suggest that an antiviral compound prevents the interaction between two viral proteins (NS3 and NS4B) that play an important role in the replication process of a virus, thereby stopping the ability of the virus to reproduce. Janssen is now moving its dengue program into clinical development.

Virus 52

Virus Clinical Development Science Disease 52

The Pharma Data

NOVEMBER 13, 2020

If not enough children are immunized against polio, the weakened virus can pass between individuals and over time genetically revert to a form that can cause paralysis. If not enough children are immunized against polio, the weakened virus can pass between individuals and over time genetically revert to a form that can cause paralysis.

Vaccine 52

Vaccine Virus Clinical Trials Licensing 52

The Pharma Data

FEBRUARY 25, 2021

Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac , its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. About TicoVac (TBE vaccine, whole virus inactivated). 2014;32(20):2375-81. Barrett PN.

FDA 52

FDA Vaccine Virus Clinical Trials 52

The Pharma Data

MARCH 16, 2021

Pascal Soriot, Chief Executive Officer, said: “The long-acting antibody combination has the potential to offer almost immediate protection to those who are not able to be vaccinated, to both prevent infection or treat the disease in patients already infected with the virus. Financial considerations. Source link:[link].

Treatment 52

Treatment Virus Trials Government 52

Codon

SEPTEMBER 29, 2024

At best, the corporations with the best models released weak versions to the public under non-commercial licenses. On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within. The pessimism of just a few years before was replaced with exuberant optimism.

Engineering 130

Engineering Virus DNA Therapies 130

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. ” Under the license agreement, the development of ABBV-47D11 will be greatly advanced. Kate Krav-Rude/Shutterstock. before expanding it into Europe. .

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52

The Pharma Data

FEBRUARY 14, 2022

This virus shows how interconnected we all are and I am proud that Belgium –and other EU countries – are now collaborating to build vaccine capacity everywhere,” said Meryame Kitir, Minister of Development Cooperation and Urban Policy of Belgium. We are opening the door to better health and wellbeing for our people.”. “At

Vaccine 52

Vaccine Licensing Licensing Science 52

The Pharma Data

AUGUST 22, 2021

AZD7442 is a combination of two LAABs – tixagevimab (AZD8895) and cilgavimab (AZD1061) – derived from B-cells donated by convalescent patients after SARS-CoV-2 virus. Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales. About AstraZeneca. Yu XQ, et al.

Trials 52

Trials Vaccine Virus Pharmacokinetics 52

The Pharma Data

JANUARY 4, 2021

05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. USA) to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. . MUNICH, Germany, Jan.

Therapies 52

Therapies Virus Disease Licensing 52

The Pharma Data

OCTOBER 26, 2020

Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” ” Panel: Direct Antivirals and Other Agents Against SARS-CoV2 Virus Date: Wednesday, October 28, 2020 Time: 10:30AM- 11:50AM ET.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

NOVEMBER 17, 2021

It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. COVID-19 Vaccine AstraZeneca is known as Vaxzevria in Europe. About AstraZeneca.

Vaccine 52

Vaccine Clinical Trials Virus Licensing 52

The Pharma Data

DECEMBER 30, 2020

31, 2020 /PRNewswire/ — ImmVira Group Company (“the Company”), a biotechnology platform dedicated to the development of oncolytic virus(“OV”) and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C financing.

Virus 52

Virus International Trials Clinical Trials 52

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

This product was developed by uniQure prior to being licensed to CSL Behring. At the same time, it is understandably important to be able to measure and characterize a treatment’s effect over time.

Therapies 119

Therapies FDA FDA Approval Treatment 119

The Pharma Data

MARCH 29, 2022

13 People at increased risk of exposure to the SARS-CoV-2 virus could also benefit from protection with Evusheld. 1,3 The reduced Fc effector function aims to minimise the risk of antibody-dependent enhancement of disease – a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.20.

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

MARCH 25, 2022

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(10) and were optimised by AstraZeneca with half-life extension and reduction of Fc effector function. 2-4 Evusheld was generally well-tolerated in the trial.(2-4).

Vaccine 52

Vaccine Virus Immune Response Trials 52

The Pharma Data

MARCH 22, 2022

Additionally, Pfizer has signed a voluntary license agreement with the Medicines Patent Pool (MPP) for its oral treatment to help expand access, pending country regulatory authorization or approval, in 95 low- and middle-income countries that account for approximately 53% of the world’s population.

Treatment 52

Treatment Virus Therapies Hospitals 52

The Pharma Data

OCTOBER 22, 2020

The collaboration will make trusted, public health information available under the Creative Commons Attribution-ShareAlike license at a time when countries face continuing resurgences of COVID-19 and social stability increasingly depends on the public’s shared understanding of the facts. . About the World Health Organization.

Licensing 52

Licensing Licensing International Government 52

The Pharma Data

APRIL 15, 2022

The test is performed by a qualified, trained operator under the supervision of a health care provider licensed or authorized by state law to prescribe tests and can provide results in less than three minutes. director of the FDA’s Center for Devices and Radiological Health. In the study, the test was shown to have 91.2%

FDA 52

FDA Licensing Licensing Production 52

The Pharma Data

JANUARY 31, 2021

Our preclinical work at Gritstone developing our powerful prime-boost vaccine technology utilized simian immunodeficiency virus (SIV) derived antigens as model antigens, which are very similar to HIV-1. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

Codon

APRIL 2, 2023

Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. Read A really simple way to isolate AAVs, which are a type of virus often used to deliver gene therapies into cells. Only about 15% of antibodies actually neutralize the new variants. Ricciardi M.J. Gene Therapy.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

AUGUST 28, 2020

UK signs deals for 90 million virus vaccine doses. The UK remains under the jurisdiction of the European Medicines Agency and its licensing scheme until the end of the Brexit transition period on 31 December 2020. Oxford coronavirus vaccine triggers immune response.

Vaccine 52

Vaccine Immune Response Nurses Government 52